<DOC>
	<DOCNO>NCT01120262</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood laboratory patient cancer may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment . PURPOSE : This research study study blood sample patient metastatic prostate cancer previously treat bicalutamide goserelin .</brief_summary>
	<brief_title>S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide Goserelin</brief_title>
	<detailed_description>OBJECTIVES : - To test association serum PSA response ( &lt; 4 ng/mL ) 7 month inherit variability germline single nucleotide polymorphism , set candidate gene , patient metastatic prostate cancer treat combination induction androgen-deprivation therapy comprise bicalutamide goserelin . OUTLINE : DNA extract whole blood serum sample analyze inherited variability germline single nucleotide polymorphism .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosed metastatic prostate cancer Accrued SWOG9346 receive androgendeprivation therapy ( ADT ) Must serum PSA value begin end 8 course ADT Must whole blood serum sample available PATIENT CHARACTERISTICS : Caucasian AfricanAmerican participant PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>